



Contra Costa Health Plan
P&T Formulary Update
June 14, 2024

Changes effective: 07/29/2024

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On June 14, 2024 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Anti-obesity • VEGF receptor inhibitors • CGRPs • Benign Prostatic Hyperplasia • Opioid Use Disorder Agents	• Contraceptive foams and devices • Phosphate Binders • Gaucher Disease
Drug Monographs	
• Rezdiffra monograph • Eohilia monograph • Filsuvez monograph • Amtagvi monograph • Lenmeldy monograph	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • CGM • Rezdiffra • Eohilia • Filsuvez • Amtagvi • Lenmeldy • VEGF receptor inhibitors <u>Updates were made to the criteria for the following agents:</u> • CGRPs <u>Criteria reviewed and unchanged:</u> • Anti-obesity medications • Benign prostatic hyperplasia • Opioid Use Disorder Agents	

- Contraceptive foams, devices
- Phosphate Binders
- Gaucher Disease

CCHP formulary changes were made to the following drugs:

- Aimovig (erenumab-aooe)
- Ajovy (fremanezumab-vfrm)
- Emgality (galcanezumab-gnlm)
- Nurtec ODT (Rimegepant)

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary (commercial and BHC members):

Medication Name & Dosage Strength	Approved Formulary Changes
Aimovig (erenumab-aooe)	Add to formulary with prior authorization
Ajovy (fremanezumab-vfrm)	
Emgality (galcanezumab-gnlm)	Remove from formulary
Nurtec ODT (rimegepant)	

New Product Reviews (including new indications)

- | | |
|---|--|
| <ul style="list-style-type: none"> • Rivfloza (nedosiran) syringe • Alvaiz (eltrombopag) oral tablets • Eohilia (budesonide) oral suspension • Amtagvi (lifileucel) IV suspension • Hem libra (emicizumab-kx wh) subcutaneous vial • RiVive (naloxone) nasal spray • Rezdiffra (resmetirom) oral tablets • Lenmeldy (atidarsagene) • Spevigo (spesolimab-sbzo) syringe | <ul style="list-style-type: none"> • Voydeya (danicopan) tablets • Ogsiveo (nirogacestat) tablets • Xcopri (cenobamate) tablets • Ojemda (tovorafenib) tablets |
|---|--|